Macular Degeneration Market Expected to Witness Significant Growth Amid Advancements in Treatment and Rising Prevalence of Retinal Disorders

Mordor Intelligence has published a new report on the Macular Degeneration Market, offering a comprehensive analysis of trends, growth drivers, and future projections.   

The global macular degeneration treatment market is projected to grow from USD 16.79 billion in 2025 to USD 25.25 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.51% during the forecast period. This growth is primarily attributed to the increasing prevalence of retinal disorders, an aging global population, and significant advancements in therapeutic options.

Key Trends

Rising Prevalence of Retinal Disorders

Age-related macular degeneration (AMD) is a leading cause of vision loss among individuals aged 50 and above. The global incidence of AMD is on the rise, with projections indicating that approximately 288 million individuals will be affected by 2040. Additionally, the prevalence of diabetic retinopathy is expected to increase to 161 million individuals by 2045. This escalating burden underscores the urgent need for effective treatment options, thereby driving market growth.

Advancements in Therapeutic Options

The development of innovative therapies, particularly anti-vascular endothelial growth factor (anti-VEGF) treatments, has revolutionized the management of wet AMD. For instance, in September 2024, Kyowa Kirin initiated a Phase-2 clinical trial to assess the efficacy of an experimental eye drop, KHK4951, for individuals with wet AMD. Such advancements are enhancing patient outcomes and expanding the treatment landscape.

Increased Research and Development Investments

Pharmaceutical companies are investing heavily in research and development to discover novel treatments for macular degeneration. Collaborations and partnerships are also facilitating the progression of gene therapy programs aimed at treating dry AMD. For example, in January 2023, Oculogenex and Forge Biologics formed a manufacturing partnership to advance Oculogenex’s gene therapy program targeting dry AMD. These investments are expected to yield more effective and diverse treatment options, propelling market growth.

Report Overview: https://www.mordorintelligence.com/industry-reports/macular-degeneration-treatment-market

Market Segmentation

By Type

• Dry Age-related Macular Degeneration: Characterized by the thinning of the macula, leading to gradual vision loss. Currently, treatment options are limited, but ongoing research into gene therapies and other interventions holds promise for future advancements.
• Wet Age-related Macular Degeneration: Involves abnormal blood vessel growth under the retina, leading to rapid vision loss. This segment holds a significant market share due to the availability of effective treatments like anti-VEGF injections.

By Stage of Disease

• Early-stage AMD: Often asymptomatic, requiring regular monitoring and lifestyle modifications to slow progression.
• Intermediate AMD: Characterized by noticeable vision changes, necessitating more frequent monitoring and potential therapeutic interventions.
• Late-stage AMD: Significant vision loss occurs, with treatments focused on preserving remaining vision and improving quality of life.

By Treatment Type

• Drugs: Includes anti-VEGF agents, corticosteroids, and emerging gene therapies.
• Devices: Implantable devices and assistive technologies designed to manage AMD symptoms and enhance visual function.
• Surgery: Laser therapies and other surgical interventions aimed at treating advanced cases of AMD.

By Route of Administration

• Intravenous Route: Used for certain systemic treatments, though less common in AMD management.
• Intravitreal Route: Direct injection into the eye, commonly employed for administering anti-VEGF therapies.

By Sales Channel

• Ambulatory Surgical Centers: Facilities providing outpatient surgical treatments for AMD.
• Hospitals: Primary centers for comprehensive AMD treatment, including diagnostics, medical therapy, and surgical interventions.
• Other Sales Channels: Includes specialty clinics and online pharmacies offering AMD-related treatments and devices.

By Geography

• North America: Currently the largest market, driven by a high prevalence of AMD, advanced healthcare infrastructure, and significant R&D activities.
• Europe: Holds a substantial market share due to an aging population and increased awareness of AMD treatments.
• Asia-Pacific: Anticipated to be the fastest-growing region, attributed to a rising elderly population and improving healthcare access.
• Middle East and Africa: Emerging markets with growing investments in healthcare infrastructure and increasing awareness of AMD.
• South America: Experiencing gradual growth due to expanding healthcare access and rising prevalence of AMD.

Get a Customized Report Tailored to Your Requirements. – https://www.mordorintelligence.com/market-analysis/disease-specific-drugs

Key Players

The macular degeneration treatment market is characterized by the presence of several key players contributing to its competitive landscape. Notable companies include:

• Novartis AG: A leading pharmaceutical company offering treatments like ranibizumab (Lucentis) for wet AMD.
• Bausch Health Companies Inc.: Provides a range of ophthalmic products, including therapies for macular degeneration.
• REGENXBIO Inc.: Focuses on the development of gene therapies targeting retinal diseases, including AMD.
• F. Hoffmann-La Roche Ltd: Develops innovative treatments for various conditions, including ophthalmic diseases like AMD.
• Regeneron Pharmaceuticals Inc.: Known for aflibercept (Eylea), a widely used anti-VEGF therapy for wet AMD.

These companies are actively engaged in strategic initiatives such as mergers and acquisitions, partnerships, and product development to enhance their market presence and meet the evolving demands of AMD treatment.

Conclusion

The global macular degeneration treatment market is on a growth trajectory, driven by rising prevalence, advancements in therapies, and increased R&D investments. The growing elderly population and the rising incidence of lifestyle-related diseases further emphasize the need for innovative solutions to manage this debilitating condition.

As pharmaceutical companies continue to develop new treatments and explore emerging therapies like gene therapy, the macular degeneration market is expected to witness significant advancements in the coming years. With the ongoing focus on personalized medicine and improved patient outcomes, the market holds immense potential for growth, ultimately aiming to reduce the global burden of vision loss caused by macular degeneration.

Industry Related Reports